Cipher Pharmaceuticals Inc T.CPH

Cipher Pharmaceuticals Reports Fourth Quarter

[Betteryear2]

(All figures are presented in U.S. Dollars)

• Cash at December 31, 2023 was $39.8 million (CDN$52.7 million) or $1.66 per outstanding common share (CDN$2.20)
• Full year adjusted EBITDA of $12.7 million, an increase of 2.2% over fiscal 2022
• Epuris revenue grew by 10% in Q4 2023 compared to Q4 2022
• Licensing revenue increased 4.1% to $8.5 million in 2023
• Product revenue increased 1.2% to $12.7 million in 2023

MISSISSAUGA, ON, March 14, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the year ended December 31, 2023.

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results (newswire.ca)

[retiredcf]

With the SP up close to 13% and closing in on the second highest trading volume day in the past year, it seems safe to conclude that the market is pleased with these results. GLTA

[GJS471]

It has been a long and winding road, so to speak, for Cipher.  I have always liked the model but not so much the execution and poor stock prices.  But I  have stuck it out for many years, and I think more is to come. . 

[retiredcf]

Although I stiil haven't been able to find any analyst coverage, it seems safe to say that judging by the continued strength of the SP together with solid trading volume, they also liked what they saw. Long and strong. GLTA

[colourama]

Absolutely great results by CPH, but am I wrong in thinking this is getting expensive? 20x TTM free cash flow, 14x TTM EBITDA. I don't see where the growth is coming from to support the multiples, unless speculating on future acquisitions.

[SushiGobbler]

People are pricing in their Truclera nail fungus cream future potential sales i believe, which has been predicted to bring in tens/hundreds of millions in revenue annually potentially if all goes well.

[Teccing]

Dipping my toe early

[retiredcf]

Smart move! GLTA